Biotech and Pharmaceuticals Medicine

More

  • Doctor: There will be isolated Zika outbreaks in US

    Dr. Scott Gottlieb, American Enterprise Institute, speaks about the threat of Zika in the U.S. as the CDC confirms a death from the virus in Puerto Rico.

  • 683 Zika cases in Puerto Rico, 1 death - CDC

    CNBC's Sue Herera reports the Center for Disease Control's confirmation of a death due to the Zika virus in Puerto Rico. The CDC also says that among the confirmed cases of the virus, 65 of them are pregnant women and five have suspected cases of the nerve disorder Guillain-Barre Syndrome.

  • Titan Pharmaceuticals Inc and privately owned Braeburn Pharmaceuticals have together developed a matchstick-sized implant that analysts expect will be approved next month, despite mixed reviews. The market for the implant could also be much bigger than first envisaged should a bill gaining bipartisan support on Capitol Hill become law.

  • A panel of FDA advisers meets next week to review risk-management plans put in place nearly four years ago to reduce misuse and abuse of long-acting painkillers, powerful opioid drugs at the center of a national wave of abuse and death. However, many experts— including a previous panel of FDA advisers— said those measures don't go far enough and that physician...

  • LONDON, April 29- A once-monthly injection for multiple sclerosis from Biogen and AbbVie has been recommended for approval by European regulators, paving the way for its launch in the coming months. The European Medicines Agency said on Friday its experts had endorsed Zinbryta, or daclizumab, for the treatment of relapsing forms of multiple sclerosis, adding a...

  • Sales of hepatitis C drugs Sovaldi and Harvoni, the company's second generation hepatitis treatment, totaled $4.29 billion, which was short of the $4.63 billion average Wall Street estimate, as compiled by ISI Evercore. "The hep C numbers are a little light in the USA and that could be due to higher rebating and more competition," said RBC Capital Markets analyst...

  • SAN DIEGO _ Tandem Diabetes Care Inc. on Thursday reported a loss of $20.5 million in its first quarter. The average estimate of 10 analysts surveyed by Zacks Investment Research was for a loss of 69 cents per share. Seven analysts surveyed by Zacks expected $17.2 million.

  • April 28- Gilead Sciences Inc's first quarter net profit fell 18 percent as hepatitis C drug sales missed Wall Street estimates, with pricing pressure leading to lower U.S. sales of hepatitis treatment Harvoni. Sales of hepatitis C drugs Sovaldi and Harvoni totaled $4.29 billion, which was short of the $4.63 billion average Wall Street estimate, as compiled by...

  • WASHINGTON— Gilead Science Inc.' s earnings tumbled more than 17 percent in the first quarter as steeper discounts and rebates on its blockbuster hepatitis C drugs cut into sales. Gilead attributed the decline to discounts given to private insurers and higher rebates for patients in government-run health plans like Medicaid. That was below the average...

  • Aetna CEO: Tight connection between cost of drugs and premiums

    Mark Bertolini, Aetna Chairman & CEO, talks about the company's quarterly earnings, Obamacare exchanges and drug pricing.

  • Icahn on Hologic

    Carl Icahn, Chairman of Icahn Enterprises, and Hologic CEO Steve MacMillan speak about their professional relationship and how they've approached the medical device company.

  • Big health care deals

    Discussing the M&A space for biotech and health care with Les Funtleyder, Asset Management Portfolio Manager at ESquared, and Michael Yee, BioTech Analyst at RBC Capital Markets

  • April 28- An imminent ruling on Acadia Pharmaceuticals Inc's drug for Parkinson's disease psychosis is being closely watched by a Bermuda- based company with a similar treatment for dementia. The decision by the U.S. Food and Drug Administration is due by May 1. Both companies' drugs are designed to treat conditions that have no specific pharmaceutical therapy...

  • April 28- AbbVie Inc placed another bet on new cancer drugs on Thursday with a $5.8 billion deal, as it seeks new sources of revenue ahead of patent expirations on its flagship $14 billion- a-year Humira arthritis drug. Shares of AbbVie fell 7.3 percent immediately after it announced the deal but pared losses to trade down only 1.7 percent at $59.64 later on...

  • Michael Neidorff, Centene

    UnitedHealth is pulling out of most state health-care exchanges, but Centene is benefiting from Medicaid expansion.

  • COPENHAGEN, April 28- Novo Nordisk said on Thursday a late-stage trial showed its new once-weekly diabetes drug significantly reduced patients' cardiovascular risks, boosting the company's hopes of maintaining its lead in the fast-growing diabetes market. Sales of semaglutide- a so called GLP-1 analog treatment- could peak at 30-35 billion Danish crowns in...

  • April 28- AbbVie Inc said it would buy privately held oncology company Stemcentrx in a deal valued at $5.8 billion to expand its portfolio of drugs to treat cancer. AbbVie also lowered it full-year adjusted profit forecast to $4.62- $4.82 per share from $4.90- $5.10. AbbVie had bought Pharmacyclics Inc for about $21 billion in March last year, giving it access to...

  • *Deal at $52.50 a share would boost Sanofi EPS immediately. LONDON/ PARIS, April 28- French drugmaker Sanofi went public with a $9.3 billion offer to buy Medivation on Thursday, setting up what could be a lengthy takeover fight after the U.S. cancer firm rebuffed its approaches. Sanofi's non-binding proposal is to buy Medivation for $52.50 per share in cash,...

  • CUPERTINO, California— Apple is edging its way a little further into health care with the release of new iPhone apps that patients can use to manage their own medical conditions— from diabetes to pregnancy and even depression. Apple says larger organizations, including the University of Rochester and hospitals at the Texas Medical Center, are working on...

  • Mark Zuckerberg, chief executive officer of Facebook Inc.,

    Creating Facebook was a bold move, but CEO Mark Zuckerberg just proposed what he said is an even bolder one.